Press Release

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, November 13th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for second quarter of financial year 2027.

NATCO records ₹1,019 Crore Consolidated Revenue and ₹203 Crore of Profit After Tax for Q2 FY27

Key Financial Highlights

- NATCO recorded consolidated total revenue of INR 1,019.4 Crore for the quarter ended 30th September 2026, as against INR 794.4 Crore for Q1FY27 and INR 1,463.0 Crore for the corresponding quarter last year
    - QoQ increase is due to better performance in the International Formulation business
    - YoY decline is largely attributable to lower Lenalidomide revenue in the current quarter which was partially offset by growth in the base business (including subsidiaries).
- The profit for the period after share of profit of associate, on a consolidated basis, is INR 202.6 Crore, as against INR 206.5 Crore for the previous quarter and INR 517.9 Crore for the corresponding quarter last year
- For the quarter, revenue of the associate company, Adcock Ingram Holdings Limited, South Africa was at INR 1,343.8 crores and profit after tax was at INR 80.5 crores
    - During the quarter, NATCO acquired additional 13.25% stake in Adcock Ingram Holding Limited taking the total holdings to 49%
    - NATCO's share of profit based on the holding as on 30th September 2026 of 49% stood at INR 29.2 crores (after adjustment relating to provisional PPA).
- The Board of Directors have declared an interim dividend of INR 1.25 per equity share of INR 2 each during Q2FY27.

Segmental Revenue Split (INR Crore)

Business Segments	Q2FY27	Q2FY26	Q1FY27
Active Pharmaceutical Ingredients (API)	61.3	53.9	66.7
Domestic Pharmaceutical Formulations	145.7	105.4	136.4
International Formulations (Incl. profit share and subsidiaries)	668.4	1,140.2	477.1
Crop Health Sciences (CHS)	61.0	52.4	40.8
Other operating and non-operating income	83.0	111.1	73.4
Total	**1,019.4**	**1,463.0**	**794.4**

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Consolidated Financial Summary (INR Crore)

Particulars	Q2FY27	Q2FY26	Q1FY27
Total Revenue	1,019.4	1,463.0	794.4
EBITDA Before Share of Associate*	310.0	679.2	245.7
EBITDA Margin (%)*	*30.4%*	*46.4%*	*30.9%*
Profit After Tax, Before Share of Profit of Associate	173.4	517.9	122.2
Share of Profit of Associate	29.2	-	84.3
Profit for the period After Share of Profit of Associate	202.6	517.9	206.5
Earnings Per Share (EPS) INR per share	*11.31*	*28.94*	*11.53*

*Includes other income

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter).

Earnings Call Details:

- *Date: 13th November 2026, Friday*
- *Time: 4.00 PM IST*
- *Pre-registration link:* Please **Click Here** to pre-register for the call

For further information please contact:

Rajeev Menon - Investor Relations

ir@natcopharma.co.in/r.menon@natcopharma.co.in